AAPL316.22-3.75 (-1.17%) ▼|ABBV248.78-7.68 (-2.99%) ▼|ABT105.04-0.54 (-0.51%) ▼|ACN179.19+0.15 (+0.08%) ▲|ADBE257.55+0.29 (+0.11%) ▲|AMAT473.00+0.21 (+0.04%) ▲|AMD514.91+9.17 (+1.81%) ▲|AMGN390.88-2.29 (-0.58%) ▼|AMT175.45-0.30 (-0.17%) ▼|AMZN252.84-4.13 (-1.61%) ▼|AVGO364.32-4.24 (-1.15%) ▼|AXP322.50-3.62 (-1.11%) ▼|BA211.19+0.36 (+0.17%) ▲|BAC61.83-0.56 (-0.90%) ▼|BKNG173.01-7.30 (-4.05%) ▼|BLK1,088.81-7.02 (-0.64%) ▼|BMY64.44-0.26 (-0.40%) ▼|BNY161.52-1.35 (-0.83%) ▼|BRK-B502.72-3.10 (-0.61%) ▼|C135.65-1.13 (-0.82%) ▼|CAT825.99+3.46 (+0.42%) ▲|CL87.45-0.96 (-1.09%) ▼|CMCSA26.06-0.27 (-1.03%) ▼|COF212.80-1.23 (-0.57%) ▼|COP136.61+1.56 (+1.16%) ▲|COST902.98-7.20 (-0.79%) ▼|CRM251.15+1.97 (+0.79%) ▲|CSCO109.96+0.79 (+0.72%) ▲|CVS96.34+0.25 (+0.26%) ▲|CVX213.35+3.35 (+1.60%) ▲|DE684.82+4.02 (+0.59%) ▲|DHR202.86-2.33 (-1.13%) ▼|DIS103.47-1.63 (-1.55%) ▼|DUK121.40+0.15 (+0.12%) ▲|EMR151.94-0.24 (-0.16%) ▼|FDX310.75-3.36 (-1.07%) ▼|GD356.58+0.03 (+0.01%) ▲|GE329.16-5.78 (-1.73%) ▼|GEV982.00+10.62 (+1.09%) ▲|GILD145.73-0.92 (-0.62%) ▼|GM85.56-0.22 (-0.26%) ▼|GOOG327.29-8.09 (-2.41%) ▼|GOOGL329.68-8.69 (-2.57%) ▼|GS1,017.52-19.16 (-1.85%) ▼|HD311.06-2.61 (-0.83%) ▼|HON208.03-0.21 (-0.10%) ▼|IBM235.36+3.25 (+1.40%) ▲|INTC103.88-0.59 (-0.56%) ▼|INTU320.05+1.12 (+0.35%) ▲|ISRG353.50+3.34 (+0.95%) ▲|JNJ268.79-0.39 (-0.14%) ▼|JPM351.52-2.03 (-0.57%) ▼|KO87.77-0.66 (-0.74%) ▼|LIN467.79-0.59 (-0.13%) ▼|LLY1,131.65+7.79 (+0.69%) ▲|LMT538.72+2.40 (+0.45%) ▲|LOW199.94-0.88 (-0.44%) ▼|LRCX320.58+0.16 (+0.05%) ▲|MA566.56-4.38 (-0.77%) ▼|MCD253.85-1.99 (-0.78%) ▼|MDLZ61.01-0.62 (-1.01%) ▼|MDT92.18-0.22 (-0.23%) ▼|META643.68+30.20 (+4.92%) ▲|MMM166.19-1.33 (-0.79%) ▼|MO67.57-0.61 (-0.89%) ▼|MRK148.14-0.34 (-0.23%) ▼|MS213.88-2.43 (-1.12%) ▼|MSFT492.73-1.22 (-0.25%) ▼|MU1,001.54+1.28 (+0.13%) ▲|NEE84.19+0.34 (+0.40%) ▲|NFLX76.60-0.17 (-0.22%) ▼|NKE37.17-0.93 (-2.45%) ▼|NOW133.49-0.75 (-0.56%) ▼|NVDA225.19-0.54 (-0.24%) ▼|ORCL162.35-0.17 (-0.10%) ▼|PEP137.42-1.03 (-0.74%) ▼|PFE27.63-0.17 (-0.61%) ▼|PG142.72-2.87 (-1.97%) ▼|PLTR170.35+0.05 (+0.03%) ▲|PM181.57-3.21 (-1.74%) ▼|QCOM179.87+5.78 (+3.32%) ▲|RTX198.29-0.55 (-0.28%) ▼|SBUX100.49-1.52 (-1.49%) ▼|SCHW107.04+0.17 (+0.16%) ▲|SO88.82-0.19 (-0.21%) ▼|SPG209.90+0.18 (+0.09%) ▲|T25.26-0.36 (-1.39%) ▼|TMO598.34-4.92 (-0.82%) ▼|TMUS181.01-0.68 (-0.37%) ▼|TSLA371.53+3.37 (+0.91%) ▲|TXN258.87-0.05 (-0.02%) ▼|UBER72.64-0.50 (-0.68%) ▼|UNH393.21-7.66 (-1.91%) ▼|UNP285.45-3.42 (-1.18%) ▼|UPS100.00-0.48 (-0.48%) ▼|USB62.07-0.44 (-0.70%) ▼|V367.71-1.11 (-0.30%) ▼|VZ49.86-0.54 (-1.07%) ▼|WFC88.22+0.25 (+0.28%) ▲|WMT105.36-0.70 (-0.66%) ▼|XOM164.76+4.05 (+2.52%) ▲|AAPL316.22-3.75 (-1.17%) ▼|ABBV248.78-7.68 (-2.99%) ▼|ABT105.04-0.54 (-0.51%) ▼|ACN179.19+0.15 (+0.08%) ▲|ADBE257.55+0.29 (+0.11%) ▲|AMAT473.00+0.21 (+0.04%) ▲|AMD514.91+9.17 (+1.81%) ▲|AMGN390.88-2.29 (-0.58%) ▼|AMT175.45-0.30 (-0.17%) ▼|AMZN252.84-4.13 (-1.61%) ▼|AVGO364.32-4.24 (-1.15%) ▼|AXP322.50-3.62 (-1.11%) ▼|BA211.19+0.36 (+0.17%) ▲|BAC61.83-0.56 (-0.90%) ▼|BKNG173.01-7.30 (-4.05%) ▼|BLK1,088.81-7.02 (-0.64%) ▼|BMY64.44-0.26 (-0.40%) ▼|BNY161.52-1.35 (-0.83%) ▼|BRK-B502.72-3.10 (-0.61%) ▼|C135.65-1.13 (-0.82%) ▼|CAT825.99+3.46 (+0.42%) ▲|CL87.45-0.96 (-1.09%) ▼|CMCSA26.06-0.27 (-1.03%) ▼|COF212.80-1.23 (-0.57%) ▼|COP136.61+1.56 (+1.16%) ▲|COST902.98-7.20 (-0.79%) ▼|CRM251.15+1.97 (+0.79%) ▲|CSCO109.96+0.79 (+0.72%) ▲|CVS96.34+0.25 (+0.26%) ▲|CVX213.35+3.35 (+1.60%) ▲|DE684.82+4.02 (+0.59%) ▲|DHR202.86-2.33 (-1.13%) ▼|DIS103.47-1.63 (-1.55%) ▼|DUK121.40+0.15 (+0.12%) ▲|EMR151.94-0.24 (-0.16%) ▼|FDX310.75-3.36 (-1.07%) ▼|GD356.58+0.03 (+0.01%) ▲|GE329.16-5.78 (-1.73%) ▼|GEV982.00+10.62 (+1.09%) ▲|GILD145.73-0.92 (-0.62%) ▼|GM85.56-0.22 (-0.26%) ▼|GOOG327.29-8.09 (-2.41%) ▼|GOOGL329.68-8.69 (-2.57%) ▼|GS1,017.52-19.16 (-1.85%) ▼|HD311.06-2.61 (-0.83%) ▼|HON208.03-0.21 (-0.10%) ▼|IBM235.36+3.25 (+1.40%) ▲|INTC103.88-0.59 (-0.56%) ▼|INTU320.05+1.12 (+0.35%) ▲|ISRG353.50+3.34 (+0.95%) ▲|JNJ268.79-0.39 (-0.14%) ▼|JPM351.52-2.03 (-0.57%) ▼|KO87.77-0.66 (-0.74%) ▼|LIN467.79-0.59 (-0.13%) ▼|LLY1,131.65+7.79 (+0.69%) ▲|LMT538.72+2.40 (+0.45%) ▲|LOW199.94-0.88 (-0.44%) ▼|LRCX320.58+0.16 (+0.05%) ▲|MA566.56-4.38 (-0.77%) ▼|MCD253.85-1.99 (-0.78%) ▼|MDLZ61.01-0.62 (-1.01%) ▼|MDT92.18-0.22 (-0.23%) ▼|META643.68+30.20 (+4.92%) ▲|MMM166.19-1.33 (-0.79%) ▼|MO67.57-0.61 (-0.89%) ▼|MRK148.14-0.34 (-0.23%) ▼|MS213.88-2.43 (-1.12%) ▼|MSFT492.73-1.22 (-0.25%) ▼|MU1,001.54+1.28 (+0.13%) ▲|NEE84.19+0.34 (+0.40%) ▲|NFLX76.60-0.17 (-0.22%) ▼|NKE37.17-0.93 (-2.45%) ▼|NOW133.49-0.75 (-0.56%) ▼|NVDA225.19-0.54 (-0.24%) ▼|ORCL162.35-0.17 (-0.10%) ▼|PEP137.42-1.03 (-0.74%) ▼|PFE27.63-0.17 (-0.61%) ▼|PG142.72-2.87 (-1.97%) ▼|PLTR170.35+0.05 (+0.03%) ▲|PM181.57-3.21 (-1.74%) ▼|QCOM179.87+5.78 (+3.32%) ▲|RTX198.29-0.55 (-0.28%) ▼|SBUX100.49-1.52 (-1.49%) ▼|SCHW107.04+0.17 (+0.16%) ▲|SO88.82-0.19 (-0.21%) ▼|SPG209.90+0.18 (+0.09%) ▲|T25.26-0.36 (-1.39%) ▼|TMO598.34-4.92 (-0.82%) ▼|TMUS181.01-0.68 (-0.37%) ▼|TSLA371.53+3.37 (+0.91%) ▲|TXN258.87-0.05 (-0.02%) ▼|UBER72.64-0.50 (-0.68%) ▼|UNH393.21-7.66 (-1.91%) ▼|UNP285.45-3.42 (-1.18%) ▼|UPS100.00-0.48 (-0.48%) ▼|USB62.07-0.44 (-0.70%) ▼|V367.71-1.11 (-0.30%) ▼|VZ49.86-0.54 (-1.07%) ▼|WFC88.22+0.25 (+0.28%) ▲|WMT105.36-0.70 (-0.66%) ▼|XOM164.76+4.05 (+2.52%) ▲|
22.5 C
New York
Wednesday, September 9, 2026

Tag: brain

newssourceFORcompanyinformationcontent1releasesmarket

Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia

SOUTH SAN FRANCISCO, July 25, 2025 (GLOBE NEWSWIRE) -- Recognify Life Sciences, a clinical-stage biotech company focused on developing treatments for cognitive impairment, today announced that its randomized, double-blind, placebo-controlled Phase 2b clinical trial evaluating inidascamine (formerly RL-007) in patients with cognitive impairment associated with schizophrenia (CIAS) did not meet its primary endpoint.

Menovelle ‘Coffee Hack’ Fixes Hot Flashes, Belly Weight Gain & Mood Swings, Research Suggests

A Natural Supplement Trend in 2025, Menovelle Helps Women Support Hormonal Balance and Metabolic Energy Without Hormone Therapy or Stimulants 
A Natural Supplement Trend in 2025, Menovelle Helps Women Support Hormonal Balance and Metabolic Energy Without Hormone Therapy or Stimulants

Amare Global Launches Skin to Mind™: Skincare Built on Neuroscience + Made with Mental Wellness in Mind

Revolutionary formulas target visible stress signals and support bliss signals at the cutaneous level for results you can see on your skin—and feel within. NEW...

Spear Bio Launches Next Generation Ultrasensitive Immunoassay Solution SPEAR UltraDetect™ to Transform Neurodegenerative Disease Research

WOBURN, Mass., July 25, 2025 /PRNewswire/ -- Spear Bio, a biotechnology company pioneering homogeneous ultrasensitive immunoassay technology, today announced the commercial launch of its...

Donanemab receives positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in early symptomatic Alzheimer’s disease

The opinion will now be referred to the European Commission for final regulatory decision on donanemab  INDIANAPOLIS, July 25, 2025 /PRNewswire/ -- Eli Lilly and...

Wellcome Photography Prize 2025: Winning Images Reveal Powerful Stories of Science and Health

Sujata Setia, Mithail Afrige Chowdhury and Steve Gschmeissner awarded £10,000 each for images exploring domestic abuse, climate migration and the hidden dangers of cholesterol 
Sujata Setia, Mithail Afrige Chowdhury and Steve Gschmeissner awarded £10,000 each for images exploring domestic abuse, climate migration and the hidden dangers of cholesterol

Algernon Announces Closing of the Private Placement Financing

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Klotho Neurosciences, Inc. to Expand Development Programs Beyond Neurology

Company to Pursue Technologies to Improve Muscle Strength, Bone Health, and Other Longevity Indicators NEW YORK, July 24, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO)...

Valeo – Résultats du 1er semestre 2025

CP résultats S1 2025 Wiztrust

Omniscient and The Jacobs Institute, Inc. Announce Strategic Partnership to Pioneer Clinical Connectomics

Omniscient and The Jacobs Institute launch Connectomics Innovation Program to advance stroke recovery and neurologic care with AI-enabled software.

Johnson & Johnson showcases latest advancements in Alzheimer’s research at AAIC 2025

Early data from robust Autonomy Phase 2b posdinemab trial demonstrate Company's leadership in multimodal biomarkers and early detection New findings highlight the central role of...

Exhale Expands THCA Collection With Two Best THCA Flower Strains: Godfather OG and Hawaiian Haze

Exhale Wellness, a leading hemp-based wellness brands, introduced two new THCA flower strains in July 2025. Read more about their features. 
Exhale Wellness, a leading hemp-based wellness brands, introduced two new THCA flower strains in July 2025. Read more about their features.

A New Chapter of Bold Leadership and Unstoppable Growth

LEHI, Utah, July 23, 2025 /CNW/ -- Amare Global, The Mental Wellness Company™, is pleased to announce a powerful new chapter; effective immediately, David...

Indivior Real World Evidence Study Finds Medications for Opioid Use Disorder, Particularly Extended-Release Buprenorphine, Reduced Odds of Emergency Department Visits for Patients with Opioid...

Extended-release buprenorphine (BUP-XR) had lower rates of hospitalizations, emergency department (ED) visits, and outpatient physician office visits compared to those receiving daily oral buprenorphine or no medications for...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsBrain

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers